Noncontrast Breast MRI During Pregnancy Using Diffusion Tensor Imaging: A Feasibility Study.


Journal

Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850

Informations de publication

Date de publication:
02 2019
Historique:
received: 02 01 2018
accepted: 01 06 2018
pubmed: 1 9 2018
medline: 24 3 2020
entrez: 1 9 2018
Statut: ppublish

Résumé

Pregnancy-associated breast cancer (PABC) is often a delayed diagnosis and contrast-enhanced MRI is contraindicated because gadolinium agents are known to cross the placenta. To investigate the feasibility and clinical utility of noncontrast breast MRI using diffusion tensor imaging (DTI) in the diagnostic workup of PABC. Prospective. Between November 2016 and January 2018, 25 pregnant participants (median gestational age: 17 weeks) were recruited from eight referral breast-care centers nationwide. Imaging indications included: newly-diagnosed PABC (n = 10, with 11 lesions), palpable mass/mastitis (n = 4), high-risk screening (n = 10), and monitoring neoadjuvant-chemotherapy response (n = 1). 1.5T, T DTI parametric maps were generated and analyzed at pixel resolution, with reference to ultrasound (US) and pathology. Two-tailed Student's t-test was applied for evaluating differences between DTI parameters of PABC vs. healthy fibroglandular tissue. Pearson's correlation test was applied to measure the agreements between λ1-based longest tumor diameter, US, and pathology. All scans were technically completed and reached diagnostic quality, except one with notable motion artifacts due to positional discomfort, which was excluded. Nine out of 11 known PABC lesions and one newly-diagnosed lesion were visible on λ1, λ2, λ3, mean diffusivity (MD), and λ1-λ3 maps, with substantial parametric contrast compared with the apparently normal contralateral fibroglandular tissue (P < 0.001 for all). Two lesions of 0.7 cm were not depicted by the diffusivity maps. Tumor diameter measured on a thresholded λ1 map correlated well with US (r = 0.97) and pathology (r = 0.95). Malignancy was excluded by DTI parametric maps in scans of symptomatic and high-risk patients, in agreement with US follow-up, except for one false-positive case. Noncontrast breast MRI is feasible and well-tolerated during pregnancy. Further studies with a larger and homogeneous cohort are required to validate DTI's additive diagnostic value, albeit this study suggests a potential adjunct role for this noninvasive approach in breast evaluation during pregnancy. 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:508-517.

Sections du résumé

BACKGROUND
Pregnancy-associated breast cancer (PABC) is often a delayed diagnosis and contrast-enhanced MRI is contraindicated because gadolinium agents are known to cross the placenta.
PURPOSE
To investigate the feasibility and clinical utility of noncontrast breast MRI using diffusion tensor imaging (DTI) in the diagnostic workup of PABC.
STUDY TYPE
Prospective.
POPULATION
Between November 2016 and January 2018, 25 pregnant participants (median gestational age: 17 weeks) were recruited from eight referral breast-care centers nationwide. Imaging indications included: newly-diagnosed PABC (n = 10, with 11 lesions), palpable mass/mastitis (n = 4), high-risk screening (n = 10), and monitoring neoadjuvant-chemotherapy response (n = 1).
FIELD STRENGTH/SEQUENCE
1.5T, T
ASSESSMENT
DTI parametric maps were generated and analyzed at pixel resolution, with reference to ultrasound (US) and pathology.
STATISTICAL TESTS
Two-tailed Student's t-test was applied for evaluating differences between DTI parameters of PABC vs. healthy fibroglandular tissue. Pearson's correlation test was applied to measure the agreements between λ1-based longest tumor diameter, US, and pathology.
RESULTS
All scans were technically completed and reached diagnostic quality, except one with notable motion artifacts due to positional discomfort, which was excluded. Nine out of 11 known PABC lesions and one newly-diagnosed lesion were visible on λ1, λ2, λ3, mean diffusivity (MD), and λ1-λ3 maps, with substantial parametric contrast compared with the apparently normal contralateral fibroglandular tissue (P < 0.001 for all). Two lesions of 0.7 cm were not depicted by the diffusivity maps. Tumor diameter measured on a thresholded λ1 map correlated well with US (r = 0.97) and pathology (r = 0.95). Malignancy was excluded by DTI parametric maps in scans of symptomatic and high-risk patients, in agreement with US follow-up, except for one false-positive case.
DATA CONCLUSION
Noncontrast breast MRI is feasible and well-tolerated during pregnancy. Further studies with a larger and homogeneous cohort are required to validate DTI's additive diagnostic value, albeit this study suggests a potential adjunct role for this noninvasive approach in breast evaluation during pregnancy.
LEVEL OF EVIDENCE
2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:508-517.

Identifiants

pubmed: 30168650
doi: 10.1002/jmri.26228
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-517

Subventions

Organisme : Israel Cancer Association
Pays : International
Organisme : Weizmann - Sheba Medical Center collaboration biomedical research grant
Pays : International
Organisme : Biomedical Research Grant
Pays : International

Informations de copyright

© 2018 International Society for Magnetic Resonance in Medicine.

Auteurs

Noam Nissan (N)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Edna Furman-Haran (E)

Department of Biological Services, Weizmann Institute of Science, Israel.

Tanir Allweis (T)

Department of General Surgery, Kaplan Medical Center, Israel.

Tehillah Menes (T)

Department of General Surgery, Souraski Medical Center, Israel.

Orit Golan (O)

Department of Radiology, Souraski Medical Center, Israel.

Varda Kent (V)

Department of Radiology, Assaf Harofeh Medical Center, Israel.

Daphna Barsuk (D)

Department of General Surgery, Assuta Medical Center, Israel.

Shani Paluch-Shimon (S)

Department of Oncology, Sheba Medical Center, Israel.

Ilana Haas (I)

Department of General Surgery, Meir Medical Center, Israel.

Malka Brodsky (M)

Meirav Center of Breast Care, Sheba Medical Center, Israel.

Asia Bordsky (A)

Department of General Surgery, Bnai Zion Medical Center, Israel.

Liat Friedman Granot (LF)

Department of Radiology, Carmel Medical Center, Israel.

Osnat Halshtok-Neiman (O)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Renata Faermann (R)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Anat Shalmon (A)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Michael Gotlieb (M)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Eli Konen (E)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Miri Sklair-Levy (M)

Department of Radiology, Sheba Medical Center, Israel.
Sackler School of Medicine, Tel Aviv University, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH